Rekombinanter MSH2 Antikörper (full length)

Produktnummer ABIN7878623

Dieser Maus Monoklonal Antikörper detektiert spezifisch MSH2 in WB und IHC (p). Es zeigt Reaktivität gegenüber Proben von Human, Hund und Cat.

Kurzübersicht für Rekombinanter MSH2 Antikörper (full length) (ABIN7878623)

Target: MSH2 (Mismatch Repair Protein 2 (MSH2))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human, Hund, Cat

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser MSH2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: RMSH2-6548

Produktdetails anti-MSH2 Antikörper

Bindungsspezifität: full length

Verwendungszweck: Recombinant MSH2 Antibody (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: Recombinant full-length human MSH2 protein was used as the immunogen for the recombinant MSH2 antibody.

Isotyp: IgG2a, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the recombinant MSH2 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the recombinant MSH2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu MSH2

Target: MSH2 (Mismatch Repair Protein 2 (MSH2))

Andere Bezeichnung: MSH2

Hintergrund: Mutations in DNA mismatch repair genes are associated with hereditary nonpolyposis colorectal cancer (HNPCC). Initially, inherited mutations in the MSH2 and MLH1 homologs of the bacterial DNA mismatch repair genes MutS and MutL were found at high frequency in HNPCC and were shown to be associated with microsatellite instability. The demonstration that 10 to 45 % of pancreatic, gastric, breast, ovarian and small cell lung cancers also display microsatellite instability has been interpreted to suggest that DNA mismatch repair is not restricted to HNPCC tumors but is a common feature in tumor initiation or progression.

Pathways: DNA Reparatur, Production of Molecular Mediator of Immune Response